ClinVar Miner

Submissions for variant NM_001018005.2(TPM1):c.284T>C (p.Val95Ala) (rs104894504)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000619092 SCV000740262 likely pathogenic Cardiovascular phenotype 2017-12-14 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Strong segregation with disease (lod >3 = >10 meioses),Rarity in general population databases (dbsnp, esp, 1000 genomes)
GeneDx RCV000159356 SCV000209302 pathogenic not provided 2012-06-11 criteria provided, single submitter clinical testing The Val95Ala mutation in the TPM1 gene has been reported previously in association with HCM. Karibe A et al. (2001) reported that the Val95Ala mutation, which was absent from 200 control individuals, co-segregates with HCM in a large family where all 14 individuals with the mutation were affected. Within this family, 11 additional individuals died due to cardiomyopathy suggesting a poor prognosis, despite a mild disease presentation. Although Val95Ala results in a conservative amino acid substitution of one non-polar amino acid with another, the substitution occurs at a position that is highly conserved in vertebrates throughout evolution. Functional study data indicate Val95Ala increases thin filament Ca2+ sensitivity and alters the rate of myosin cycling. Another mutation in a nearby codon (Ile92Thr) has been reported in association with DCM (Hershberger R et al., 2010), further supporting the functional importance of this region of the protein. Val95Ala was not observed in up to 400 alleles in control individuals of African American and Caucasian ancestry tested at GeneDx, indicating it is not a common benign polymorphism in these populations. In summary, Val95Ala in the TPM1 gene is interpreted as a disease-causing mutation. The variant is found in HCM panel(s).
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000211870 SCV000203873 pathogenic Hypertrophic cardiomyopathy 2014-10-06 criteria provided, single submitter clinical testing The Val95Ala variant in TPM1 has been reported in 1 Spanish-American individual with HCM and segregated with disease in >10 affected family members (Karibe 200 1). It was absent from large population studies. In vitro functional studies ind icate this variant may impact protein function (Karibe 2001, Mathur 2011, Bai 20 11, Wang 2011); however, in vitro assays may not accurately represent biological function. Valine (Val) at position 95 is highly conserved in mammals and across evolutionarily distant species and the change to alanine (Ala) was predicted to be pathogenic using a computational tool clinically validated by our laboratory . This tool's pathogenic prediction is estimated to be correct 94% of the time ( Jordan 2011). In summary, this variant meets our criteria to be classified as pa thogenic for HCM in an autosomal dominant manner (http://www.partners.org/person alizedmedicine/LMM) based upon segregation studies, absence from controls, and f unctional evidence.
Leiden Muscular Dystrophy (TPM1) RCV000013273 SCV000045881 not provided Familial hypertrophic cardiomyopathy 3 2012-04-15 no assertion provided curation
OMIM RCV000013273 SCV000033520 pathogenic Familial hypertrophic cardiomyopathy 3 2001-01-02 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.